Filed Pursuant to Rule 433
Issuer Free Writing Prospectus dated September 9, 2024
Relating to Preliminary Prospectus Supplement dated September 9, 2024 and
Prospectus dated July 27, 2023
Registration No. 333-269452

**Pricing Terms** 

NewtekOne, Inc.

\$75,000,000 8.625% Fixed Rate Senior Notes due 2029

> Pricing Term Sheet September 9, 2024

The following sets forth the final terms of the 8.625% Fixed Rate Senior Notes due 2029 (the "Notes") and should only be read together with the preliminary prospectus supplement, dated September 9, 2024, together with the accompanying prospectus dated, July 27, 2023, relating to these securities (together, the "Preliminary Prospectus") and supersedes the information in the Preliminary Prospectus to the extent inconsistent with the information in the Preliminary Prospectus. In all other respects, this pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus. Terms used herein but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus. All references to dollar amounts are references to U.S. dollars.

NewtekOne, Inc., a Maryland corporation (the "Company")

**Issuer:** 

**Type of Note:** 

Title of the Securities:	8.625% Fixed Rate Senior Notes due 2029	
Rating:*	Egan Jones Ratings Company: BBB+	
Initial Aggregate Principal Amount Being Offered:	\$75,000,000	
Over-Allotment Option:	Up to \$11,250,000 aggregate principal amount of Notes within 30 days of the date hereof solely to cover over-allotments, if any.	
Issue Price:	\$25.00	
Principal Payable at Maturity:	100% of the aggregate principal amount. The outstanding principal amount of the Notes will be payable on the stated maturity date at the office of the trustee, paying agent and security registrar for the Notes or at such other office as the Company may designate.	

Fixed rate note

Listing:	The Company intends to list the Notes on the Nasdaq Global Market under the ticker symbol "NEWTH" within 30 days of the original issue date.	
Stated Maturity Date:	October 15, 2029	
Interest Rate:	8.625% per year	
<b>Underwriting Discount:</b>	3.00% of principal amount	
Net Proceeds to the Issuer, before Expenses:	\$72,750,000 (or \$83,662,500 total assuming the over-allotment option is exercised in full)	
Day Count Basis:	360-day year of twelve 30-day months	
Trade Date:	September 9, 2024	
Settlement Date:	September 16, 2024 (T + 5)**	
<b>Date Interest Starts Accruing:</b>	September 16, 2024	
Interest Payment Dates:	Each January 15, April 15, July 15 and October 15, commencing on January 15, 2025. If an interest payment date falls on a non-business day, the applicable interest payment will be made on the next business day and no additional interest will accrue as a result of such delayed payment.	
Interest Periods:	The initial interest period will be the period from and including September 16, 2024, to, but excluding, the initial interest payment date, and the subsequent interest periods will be the periods from and including an interest payment date to, but excluding, the next interest payment date or the stated maturity date, as the case may be.	
Specified Currency:	U.S. Dollars	

**Denominations:** 

**Business Day:** 

The Company will issue the Notes in denominations of \$25 and integral multiples of \$25 in excess thereof.

Each Monday, Tuesday, Wednesday, Thursday and Friday that is not a day on which banking institutions in New York City or the place of payment are authorized or required by law or executive order to close.

**Optional Redemption:** 

The Notes may be redeemed in whole or in part at any time or from time to time at the Company's option on or after October 15, 2026, upon not less than 15 days nor more than 60 days written notice to holders prior to the date fixed for redemption thereof, at a redemption price of 100% of the outstanding principal amount of the Notes to be redeemed plus accrued and unpaid interest payments otherwise payable for the then-current quarterly interest period accrued to, but excluding, the date fixed for redemption.

CUSIP / ISIN:

652526 872/US6525268727

**Use of Proceeds:** 

The Company intends to use these proceeds for funding of investments, repayment of existing debt, and general corporate purposes.

Joint Book-Running Managers:

Morgan Stanley & Co. LLC Keefe, Bruyette & Woods, Inc. Raymond James & Associates, Inc. UBS Securities LLC

Trustee, Paying Agent, and Security Registrar:

U.S. Bank Trust Company, National Association

- \* Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.
- \*\* Under Rule 15c6-1 of the Securities Exchange Act of 1934, as amended, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes on any date prior to the business day before delivery thereof will be required, by virtue of the fact that the Notes initially will settle T+5, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade the Notes prior to their date of delivery hereunder should consult their own advisors.

Investors are advised to carefully consider the investment objective, risks, charges and expenses of the Company before investing. The Preliminary Prospectus, which has been filed with the U.S. Securities and Exchange Commission ("SEC"), contains this and other information about the Company and should be read carefully before investing.

This pricing term sheet and the Preliminary Prospectus are not offers to sell or the solicitation of offers to buy, nor will there be any sale of the Notes referred to in this pricing term sheet, in any jurisdiction where such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction.

A shelf registration statement relating to these securities is on file with, and has been declared effective by, the SEC. Before you invest, you should read the prospectus in that registration statement, the Preliminary Prospectus and other documents the Company has filed with the SEC for more complete information about the Company and this offering. You may obtain these documents for free by visiting EDGAR on the SEC Web site at <a href="https://www.sec.gov">www.sec.gov</a>. Alternatively, the Company, the underwriters or any dealer participating in the offering will arrange to send you the Preliminary Prospectus if you request it from Morgan Stanley & Co.

LLC at 1-866-718-1649 or by email at prospectus@morganstanley.com, from Keefe, Bruyette & Woods, USCapitalMarkets@kbw.com, from Raymond James & Associates, Inc. at 1-800-248-8863 or by email a from UBS Securities LLC at 1-888-827-7275 or by email at ol-prospectus-request@ubs.com.	Inc. at 1-800-966-1559 or by email at the prospectus@raymondjames.com, and